MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'bioMerieux Press Releases' source. Thu, 09 Feb 2012 18:15:08 +0100 http://www.medworm.com/index.php?rid=5624898&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_266 Sales: Up 6.5% at constant exchange rates Including 4.1% organic growth Double-digit growth* in 11 countries Including: India** (up 28%), China (up 20%), Brazil (up 18%) and Turkey (up 18%) Sustained momentum in clinical microbiology, up 8.2%* Instrument sales up a robust 7.9%* * At constant exchange rates and comparable business base ** Excluding the impact of the termination of a distribution contract for non-strategic products (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=5624898 Mon, 23 Jan 2012 23:00:00 +0100 5624898 http://www.medworm.com/index.php?rid=5512499&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_265 At the request of the French “Autorité des Marchés Financiers”, bioMérieux, a world leader in the field of in vitro diagnostics, completes the information in its December 7th press release on its 2011 sales objective, specifying that it has not changed the 2011 objective for operating income before non-recurring items that was previously announced. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=5512499 Tue, 13 Dec 2011 23:00:00 +0100 5512499 http://www.medworm.com/index.php?rid=5483453&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_264 bioMérieux, a world leader in the field of in vitro diagnostics,announces that, based on preliminary data, sales growth at constant exchange rates, for the eleven months ended November 30, 2011, amounted to 5.5%, with 3.4% organic growth. The deteriorating market conditions are impacting the acceleration of sales expected at the end of the year. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=5483453 Tue, 06 Dec 2011 23:00:00 +0100 5483453 http://www.medworm.com/index.php?rid=5428229&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_263 As the world leader in microbiology and a pioneer in diagnostics for antimicrobial resistance detection and susceptibility testing (AST), bioMérieux actively supports the annual European Antibiotic Awareness Day, organized today by the ECDC.1 bioMérieux subsidiaries throughout the world are providing educational tools for healthcare professionals to help increase public awareness about this serious issue. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=5428229 Thu, 17 Nov 2011 23:00:00 +0100 5428229 http://www.medworm.com/index.php?rid=5396999&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_262 bioTheranostics, Inc., a bioMérieux company that develops innovative oncology diagnostic tests to drive personalized treatment, today announced clinical study findings that link CancerTYPE ID® molecular testing with improved patient outcome. Patients in which CancerTYPE ID predicted a colorectal site of origin that subsequently received site-specific therapy had a median survival three times that of what has been reported in patients treated empirically for cancer of unknown primary (CUP). These results make CancerTYPE ID the only marketed molecular cancer classifier to demonstrate therapeutic response and patient benefit based on molecular tumor profiling. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=5396999 Mon, 07 Nov 2011 23:00:00 +0100 5396999 http://www.medworm.com/index.php?rid=5343626&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_261 Sales: Up 5.2% at constant exchange rates Including 4% organic growth Robust 8% organic growth in clinical microbiology Double-digit organic growth continues in Asia-Pacific and Latin America (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=5343626 Wed, 19 Oct 2011 22:00:00 +0100 5343626 http://www.medworm.com/index.php?rid=5281692&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_260 Communiqué de mise à disposition de la note d’information de bioMérieux et de la note en réponse d’AES Chemunex visées par l’AMF, ainsi que des informations relatives aux caractéristiques notamment juridiques, financières et comptables de bioMérieux et d’AES Chemunex.Terme du retrait obligatoire : 0,55 euro par action AES Chemunex (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=5281692 Tue, 27 Sep 2011 22:00:00 +0100 5281692 http://www.medworm.com/index.php?rid=5204381&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_259 Operating income before non-recurring items Up 5.2% At 17.8% of sales Two strategic acquisitions: AES Laboratoire, making bioMérieux world leader in food testing ARGENE, specialized in molecular diagnostics for immunocompromised patients (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=5204381 Mon, 05 Sep 2011 22:00:00 +0100 5204381 http://www.medworm.com/index.php?rid=5076447&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_258 bioTheranostics, a bioMérieux company that develops innovative oncology diagnostic tests to support targeted disease management, announced today study results published in the next issue of the Journal of Molecular Diagnostics related to the clinical validity and the clinical utility of CancerTYPE ID®, its 92-gene molecular classification test to aid in the determination of the origin of a tumor. The company also announced Medicare reimbursement coverage. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=5076447 Wed, 27 Jul 2011 22:00:00 +0100 5076447 http://www.medworm.com/index.php?rid=5057285&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_257 bioMérieux has today acquired the entire capital and voting rights of Skiva (441 886 728 R.C.S. Paris), the parent company of the AES Chemunex group. Through this transaction, bioMérieux now holds, indirectly, 99.51% of the capital and voting rights of AES Chemunex, a company listed on NYSE Euronext Paris (compartment B, ISIN: FR 0010158642). (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=5057285 Thu, 21 Jul 2011 22:00:00 +0100 5057285 http://www.medworm.com/index.php?rid=5048421&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_254 bioMérieux, a world leader in the field of in vitro diagnostics, announced that it has acquired ARGENE, a French company specialized in molecular diagnostics. This acquisition is bioMérieux’s tenth in the last five years. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=5048421 Mon, 18 Jul 2011 22:00:00 +0100 5048421 http://www.medworm.com/index.php?rid=5048420&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_256 At constant exchange rates and comparable business base* First-half sales up 4.3% Second-quarter sales accelerate: up 5.1% - Good performance in North America confirmed: up 5.1% - Strong increase in China: up 35% Two strategic acquisitions during the period Confirmation of the 2011 objective for sales growth Jean-Luc Bélingard, Chairman of the Board, takes on the role of CEO, heading the Management Committee, and Stéphane Bancel joins Institut Mérieux as Senior Advisor * Excluding the impact of discontinuing culture media for the routine clinical test business in North America (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=5048420 Mon, 18 Jul 2011 22:00:00 +0100 5048420 http://www.medworm.com/index.php?rid=4991875&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_253 Over 70 international experts in medicine, infectious diseases, microbiology and epidemiology, from every continent, gathered at the Fondation Mérieux’s Conference Center for the third edition of the World HAI Forum on healthcare-associated infections, a bioMérieux initiative. Forum participants call upon national and international health authorities and policy makers, the medical and veterinary communities, Industry, and the general public to take action to avoid an impending public health catastrophe caused by the emergence and spread of bacteria that are resistant to all antibiotics. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=4991875 Wed, 29 Jun 2011 22:00:00 +0100 4991875 http://www.medworm.com/index.php?rid=4967653&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_252 bioMérieux, a world leader in the field of in vitro diagnostics, today announced the launch of a new, innovative food safety testing method, VIDAS® UP Salmonella (SPT). This new food safety solution utilizes recombinant bacteriophage (phage) proteins, which offer best-in-class specificity and sensitivity for the targeted capture and detection of Salmonella bacteria in food and environmental samples. The technology complements the company’s VIDAS E. coli O157 (including H7) phage technology for the detection of Escherichia coli O157:H7. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=4967653 Tue, 21 Jun 2011 22:00:00 +0100 4967653 http://www.medworm.com/index.php?rid=4910484&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_251 bioTheranostics, Inc., a bioMérieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company’s CancerTYPE ID®, and Breast Cancer IndexSM. Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=4910484 Mon, 06 Jun 2011 22:00:00 +0100 4910484 http://www.medworm.com/index.php?rid=4876183&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_250 bioMérieux, a world leader in the field of in vitro diagnostics, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its NucliSENS EasyQ® MRSA, an automated molecular test for Methicillin Resistant Staphylococcus aureus (MRSA). (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=4876183 Mon, 23 May 2011 22:00:00 +0100 4876183 http://www.medworm.com/index.php?rid=4847277&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_249 bioMérieux, a world leader in the field of in vitro diagnostics, has signed an agreement to acquire AES Laboratoire, a leading French group, specialized in industrial microbiological control, for 183 million euros. This will be bioMérieux’s ninth acquisition in five years and its third in the area of industrial applications. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=4847277 Thu, 19 May 2011 22:00:00 +0100 4847277 http://www.medworm.com/index.php?rid=4788223&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_248 Labor Berlin and bioMérieux announce the signature of an agreement to create a Center of Excellence for microbiology and enhanced laboratory automation. The center will be located at Europe’s largest hospital laboratory, serving more than 8,000 in-house patients in Berlin and handling over 23 million patient analyses a year. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=4788223 Wed, 04 May 2011 22:00:00 +0100 4788223 http://www.medworm.com/index.php?rid=4741815&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_247 Sales growth: 3.5% like-for-like Strong momentum in North America Temporary slowdown in China and India Robust growth in clinical microbiology 2011 sales growth objective confirmed at 5% to 6% (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=4741815 Wed, 20 Apr 2011 22:00:00 +0100 4741815 http://www.medworm.com/index.php?rid=4708719&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_246 Innovative system designed by microbiologists for microbiologists helps a growing number of labs achieve substantial productivity gains (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=4708719 Tue, 12 Apr 2011 22:00:00 +0100 4708719 http://www.medworm.com/index.php?rid=4559459&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_244 Sales up 6.4%*, excluding H1N1 impact Improvement in operating margin: +13%** Major strategic and operational advances The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met today and approved the consolidated financial statements for the year ended December 31, 2010. The meeting was chaired by Jean-Luc Bélingard and attended by the Statutory Auditors. The financial statements have been audited and the Statutory Auditors will be issuing an unqualified opinion in the coming days. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=4559459 Mon, 07 Mar 2011 23:00:00 +0100 4559459 http://www.medworm.com/index.php?rid=4521559&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_242 The two companies leverage combined expertise in therapeutics and in diagnostics to improve patient care (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=4521559 Thu, 24 Feb 2011 23:00:00 +0100 4521559 http://www.medworm.com/index.php?rid=4590524&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_245 Combination of Philips’ Magnotech technology and bioMérieux’s assay technology achieves the performance requirements of rapid diagnostic testing in point-of-care applications (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=4590524 Wed, 26 Jan 2011 23:00:00 +0100 4590524 http://www.medworm.com/index.php?rid=4370475&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_241 At constant exchange rates and scope of consolidation: - Sales growth: 4.9% - Excluding the H1N1 impact, sales growth: 6.4% vs. 6.2% in 2009 - Rapid rise in “Emerging 7” sales: + 27%, excluding the H1N1 impact - Strong growth drivers   • Clinical microbiology: + 7.6%   • VIDAS®: + 9.2%   • Industrial applications: + 8.1% - Robust instrument sales: + 19.5% (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=4370475 Tue, 18 Jan 2011 23:00:00 +0100 4370475 http://www.medworm.com/index.php?rid=4330343&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_239 (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=4330343 Sun, 09 Jan 2011 23:00:00 +0100 4330343 http://www.medworm.com/index.php?rid=4309036&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_238 A world leader in in vitro diagnostics, bioMérieux announces the appointment of James P. Whelan as Executive Vice President of Commercial Services. In this newly created role, he will be responsible for reinforcing bioMérieux’s global service offering. This enhanced offering will include expanded customer lab audits, laboratory accreditation support and comprehensive scientific training programs. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=4309036 Mon, 03 Jan 2011 23:00:00 +0100 4309036 http://www.medworm.com/index.php?rid=4280761&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_237 (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=4280761 Mon, 20 Dec 2010 23:00:00 +0100 4280761 http://www.medworm.com/index.php?rid=4252590&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_236 bioTheranostics, a bioMérieux company that develops innovative oncology diagnostic tests to support targeted disease management, announced today new findings from a clinical study evaluating the company’s Breast Cancer Index (BCI) molecular oncology test. Data from the study were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=4252590 Thu, 09 Dec 2010 23:00:00 +0100 4252590 http://www.medworm.com/index.php?rid=4218970&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_235 bioMérieux announced today that, as part of a restructuring of its culture media business in the U.S. and Canada, it will phase out the manufacturing of its routine prepared media for clinical applications and will transfer the production of all other products manufactured at its Portland, Oregon site to other locations. The site became part of bioMérieux two years ago when it acquired PML Microbiologicals Inc., a provider of culture media and microbiological solutions in North America. These products, for both clinical and industrial applications, included routine prepared media as well as innovative and proprietary technologies such as the LyfoCults® range. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=4218970 Tue, 30 Nov 2010 23:00:00 +0100 4218970 http://www.medworm.com/index.php?rid=4132593&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_234 Co-development of assays and co-distribution of a fully integrated molecular platform due for launch in 2012. bioMérieux gains exclusive rights in microbiology. bioMérieux takes equity stake in Biocartis. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=4132593 Wed, 03 Nov 2010 23:00:00 +0100 4132593 http://www.medworm.com/index.php?rid=4117171&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_233 The bioMérieux Board of Directors today approved Alain Mérieux's proposal to hand over his responsibilities as Président Directeur Général of bioMérieux to Jean-Luc Bélingard, effective January 1, 2011. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=4117171 Mon, 25 Oct 2010 22:00:00 +0100 4117171 http://www.medworm.com/index.php?rid=4096086&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_232 bioMérieux, a world leader in in vitro diagnostics, today released its business review for the nine months ended September 30, 2010. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=4096086 Thu, 21 Oct 2010 22:00:00 +0100 4096086 http://www.medworm.com/index.php?rid=3935725&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_231 Continued Profitability Growth Operating income before non-recurring items up 10.8% Net income up 13.7% Two acquisitions in China and five new partnership agreements A solid R&D pipeline An ambitious industrial plan (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3935725 Sun, 05 Sep 2010 22:00:00 +0100 3935725 http://www.medworm.com/index.php?rid=3801926&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_230 bioMérieux, a world leader in the field of in vitro diagnostics, and Hyglos GmbH, the leader in applied phage protein technology, today announced that a team of scientists who developed a new diagnostic tool for food microbiologists is the recipient of the 2010 Food Safety Innovation Award given by the International Association of Food Protection (IAFP). Visit www.biomerieux-usa.com or www.biomerieux-usa.com/iafp2010 (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3801926 Wed, 28 Jul 2010 22:00:00 +0100 3801926 http://www.medworm.com/index.php?rid=3786043&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_229 Sales: €651 million Up 6% at constant exchange rates and scope of consolidation Strong performance of clinical and industrial microbiology as well as VIDAS® Robust growth in emerging countries 2010 operating margin objective confirmed (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3786043 Wed, 21 Jul 2010 22:00:00 +0100 3786043 http://www.medworm.com/index.php?rid=3766787&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_228 A world leader in in vitro diagnostics, bioMérieux today announced the appointment of Jacques L. Baudin as Vice President, Commercial Operations Information Technology. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3766787 Sun, 18 Jul 2010 22:00:00 +0100 3766787 http://www.medworm.com/index.php?rid=4330344&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_240 (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=4330344 Thu, 08 Jul 2010 22:00:00 +0100 4330344 http://www.medworm.com/index.php?rid=3635375&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_227 bioTheranostics, a bioMérieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company’s CancerTYPE ID® and Breast Cancer Index® molecular oncology tests. Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3635375 Sat, 05 Jun 2010 22:00:00 +0100 3635375 http://www.medworm.com/index.php?rid=3595162&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_226 Innovative solution optimizes laboratory workflow and clinical information management. A world leader in in vitro diagnostics, bioMérieux presented Myla™, a revolutionary new middleware solution to improve connectivity, laboratory workflow and information management, at the 110th General Meeting of the American Society for Microbiology (ASM) in San Diego. Part of bioMérieux’s FMLA™* solutions and services, Myla is an intelligent browser-based application that consolidates and manages microbiology data generated from a variety of sources and converts these data into actionable information for treatment decisions. Designed to transform the way that laboratory managers and technicians work, Myla recaptures time spent on information retrieval and reporting activities through a simple d... bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3595162 Mon, 24 May 2010 22:00:00 +0100 3595162 http://www.medworm.com/index.php?rid=3585017&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_225 Shimadzu and bioMérieux announce today that they have entered into a partnership to commercialize a mass spectrometry system for bacterial identification in microbiology laboratories. bioMérieux will work with Shimadzu and their subsidiary, Kratos Analytical, to adapt their linear MALDI-TOF* mass spectrometry technology for optimized integration into the microbiology laboratory workflow. This new solution is planned for commercialization by bioMérieux in 2010, together with the microbial database acquired from AnagnosTec. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3585017 Thu, 20 May 2010 22:00:00 +0100 3585017 http://www.medworm.com/index.php?rid=3569621&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_224 bioMérieux plays a driving role in Sino-French healthcare cooperation:   • Organization of seminar on emergency medicine • Inauguration of Sino-French Emergency Satellite Lab at Xinhua Hospital • Renewal and extension of the partnership with Fudan University Shanghai Cancer Hospital • Pilot project with the Shanghai Health Bureau on decentralized diagnostics in Community and County Healthcare Centers (CHC)   bioMérieux, a leader in the field of in vitro diagnostics, present in China for 22 years, is working closely with Chinese healthcare professionals and institutions to address major public health issues through a number of initiatives and partnerships. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3569621 Sun, 16 May 2010 22:00:00 +0100 3569621 http://www.medworm.com/index.php?rid=3569620&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_223 Manuel Mendez to serve as Executive Vice President, Commercial Operations for bioMérieux Inc. A world leader in in vitro diagnostics, bioMérieux today announced the appointment of Manuel O. Mendez as Executive Vice President, North American Commercial Operations of bioMérieux, Inc. His new position becomes effective May 17, 2010. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3569620 Sun, 16 May 2010 22:00:00 +0100 3569620 http://www.medworm.com/index.php?rid=3548917&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_222 bioMérieux and GlaxoSmithKline (GSK) have signed an agreement to develop a novel molecular test for cancer. In this new collaboration, the two companies will develop a theranostic test to aid oncologists in choosing the appropriate treatment for metastatic melanoma (skin cancer). (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3548917 Sun, 09 May 2010 22:00:00 +0100 3548917 http://www.medworm.com/index.php?rid=3490121&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_221 Exclusive agreement to bring state-of-the-art genome sequencing technology to the in vitro diagnostics market. bioMérieux takes equity stake in Knome. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3490121 Tue, 20 Apr 2010 22:00:00 +0100 3490121 http://www.medworm.com/index.php?rid=3490120&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_220 Sales up 6.4% at constant exchange rates and scope of consolidation. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3490120 Tue, 20 Apr 2010 22:00:00 +0100 3490120 http://www.medworm.com/index.php?rid=3459838&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_219 Innovative software: consolidates and transforms microbiology laboratory data into actionable information for treatment decisions recaptures time for lab managers through efficiency gains and full control of lab workflow A world leader in in vitro diagnostics, bioMérieux presented Myla™, a paradigm-shifting software application, at the European Congress of Clinical Microbiology and Infectious Diseases in Vienna, Austria. Myla is a browser-based application that provides microbiology laboratory managers and technicians with a set of tools to revolutionize the way they work. It was designed by microbiologists for microbiologists to recapture the time spent on information retrieving and reporting activities through improved connectivity, laboratory workflow and information management. Fo... bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3459838 Sun, 11 Apr 2010 22:00:00 +0100 3459838 http://www.medworm.com/index.php?rid=3459837&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_218 bioMérieux announces today that it has agreed on the terms for the acquisition of certain assets from AnagnosTec, a company based in the greater Berlin area, specialized in microbial identification with MALDI-TOF* mass spectrometry technology. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3459837 Sun, 11 Apr 2010 22:00:00 +0100 3459837 http://www.medworm.com/index.php?rid=3448332&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_217 The award highlights the automated media streaker’s breakthrough technology. A world leader in in vitro diagnostics, bioMérieux announced today that its automated media streaker, PREVI™ Isola has received a 2010 Medical Design Excellence Award for contributions and advances in the design of medical products. This exclusive award recognizes products for their design and engineering features, including user-related functions that improve healthcare delivery and change traditional medical attitudes or practices. PREVI Isola was designed to revolutionize front-end media processing tasks, and it is a critical component in bioMérieux’s complete range of solutions and services for Full Microbiology Lab Automation (FMLA™): www.biomerieux-diagnostics.com/fmla (Source: bioMerieux Press Rel... bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3448332 Wed, 07 Apr 2010 22:00:00 +0100 3448332 http://www.medworm.com/index.php?rid=3342160&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_216 A powerful strategic vision for 2010-2015, driven by innovation and international development. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3342160 Sun, 07 Mar 2010 23:00:00 +0100 3342160 http://www.medworm.com/index.php?rid=3342159&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_215 Solid operating and financial performance: Strong growth in sales: up 10.4% - At constant exchange rates Significant increase in operating margin: up 14.1%, at 17.4% of sales   The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on Friday, March 5, 2010 to approve the consolidated financial statements for the year ended December 31, 2009. The meeting was chaired by Alain Mérieux and attended by the Statutory Auditors. The financial statements have been audited and the Statutory Auditors are in the process of issuing an unqualified opinion. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3342159 Sun, 07 Mar 2010 23:00:00 +0100 3342159 http://www.medworm.com/index.php?rid=3603042&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_214 bioTheranostics, a bioMérieux company that discovers, develops and commercializes innovative molecular diagnostic tests in oncology, announces the launch of an expanded tumor-type database for its flagship product, CancerTYPE ID®, and the launch of KRAS mutational testing. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3603042 Wed, 03 Mar 2010 23:00:00 +0100 3603042 http://www.medworm.com/index.php?rid=3334755&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_214 bioTheranostics, a bioMérieux company that discovers, develops and commercializes innovative molecular diagnostic tests in oncology, announces the launch of an expanded tumor-type database for its flagship product, CancerTYPE ID®, and the launch of KRAS mutational testing. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3334755 Wed, 03 Mar 2010 23:00:00 +0100 3334755 http://www.medworm.com/index.php?rid=3197267&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_213 bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for fourth-quarter and full-year 2009. Net sales amounted to €1,223 million in 2009, an increase of 7.7% from the €1,111 million reported in 2008, at constant exchange rates and scope of consolidation (like-for-like). For the fourth quarter alone, net sales amounted to €328 million, compared to €311 million for the prior-year period, up 7.5% like-for-like. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3197267 Thu, 21 Jan 2010 23:00:00 +0100 3197267 http://www.medworm.com/index.php?rid=3171372&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_212 Company to leverage new production site to capture growth in China and expand Point of Care and rapid diagnostics offer for both emerging and developed countries. A world leader in in vitro diagnostics, bioMérieux announced today the acquisition of the rapid test manufacturer, Meikang Biotech, and its large production site in Shanghai. This important milestone will reinforce bioMérieux’s position in the Point of Care and rapid test markets for both emerging and developed countries. The acquisition highlights bioMérieux’s continued business expansion in fast-growing emerging markets, giving the company fully-owned, integrated manufacturing and R&D capabilities in China. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3171372 Wed, 13 Jan 2010 23:00:00 +0100 3171372 http://www.medworm.com/index.php?rid=3148694&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_211 Fully automated handheld diagnostic test devices designed to improve diagnosis and disease management in critical care settings within hospitals. Royal Philips Electronics (NYSE: PHG, AEX: PHI) and bioMérieux (NYSE Euronext: BIM) today announced that they have signed an agreement to jointly develop fully automated handheld diagnostic testing solutions for hospital use that can be deployed at the point-of-care – i.e. close to the patient. The collaboration aims to improve diagnosis and management of disease in critical care settings within hospitals (for example, Emergency Departments, Coronary Units and Intensive Care Units (ICUs)). (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3148694 Wed, 06 Jan 2010 23:00:00 +0100 3148694 http://www.medworm.com/index.php?rid=3092341&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_210 - Independent studies validate the utility of THEROS BCI® for risk stratification of early stage breast cancer patients and prediction of response to commonly used aromatase inhibitor – bioTheranostics, a bioMérieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from three studies using the company’s breast cancer molecular test. Data from the studies were presented this week at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3092341 Fri, 11 Dec 2009 23:00:00 +0100 3092341 http://www.medworm.com/index.php?rid=3074986&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_209 Alain Mérieux confirms the Institute’s commitment to meeting new medical and public health challenges. Mérieux Alliance, the Mérieux family holding company announces today that it changes its name to take on the historic name of Institut Mérieux. At a press conference held in Paris, Alain Mérieux reviewed the important role played by industrial biology in the face of major public health challenges including infectious diseases, cancer, personalized medicine, theranostics and nutrition. Along with Alexandre Mérieux and the management teams, he outlined the many strengths that Institut Mérieux and its companies—bioMérieux, Transgene, ABL and Silliker— will rely upon to meet these challenges in three strategic areas: in vitro diagnostics, immunotherapy, food safety and nutrit... bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3074986 Sun, 06 Dec 2009 23:00:00 +0100 3074986 http://www.medworm.com/index.php?rid=3051669&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_208 bioMérieux, a world leader in the field of in vitro diagnostics, today announced that it has sold all of its shares in ExonHit Therapeutics S.A. These shares had been acquired in November 2005, at the initial public offering of ExonHit Therapeutics and their sale is part of bioMérieux's regular stock portfolio management. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3051669 Wed, 02 Dec 2009 23:00:00 +0100 3051669 http://www.medworm.com/index.php?rid=3051668&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_207 bioMérieux and the CEA (French Atomic Energy Commission) announce today a long-term strategic partnership, intensifying their research collaboration to develop novel technologies for improved infectious disease management. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=3051668 Wed, 02 Dec 2009 23:00:00 +0100 3051668 http://www.medworm.com/index.php?rid=2999137&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_206 bioMérieux has signed an agreement with GlaxoSmithKline to develop a predictive test to help clinicians select the most appropriate treatment for different segments of breast cancer patients. This test, based on emerging biomarkers, will be intended for use in both adjuvant and metastatic breast cancer settings, subject to regulatory approvals. Over 500,000 new cases of breast cancer are diagnosed each year in the US and Europe alone and predictive tests have been shown to improve outcomes for these patients. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2999137 Mon, 16 Nov 2009 23:00:00 +0100 2999137 http://www.medworm.com/index.php?rid=2984429&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_205 A world leader in the field of in vitro diagnostics, bioMérieux has adapted its molecular NucliSENS EasyQ® Influenza A/B test to include the new A(H1N1) strain. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2984429 Wed, 11 Nov 2009 23:00:00 +0100 2984429 http://www.medworm.com/index.php?rid=2966713&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_204 Methicillin Resistant Staphylococcus aureus (MRSA) is the most prevalent multi-drug resistant bacteria and a growing threat to health. bioMérieux, a world leader in the field of in vitro diagnostics, today launched NucliSENS EasyQ® MRSA, a new automated test for Methicillin Resistant Staphylococcus aureus (MRSA), one of the leading causes of healthcare-associated infections. NucliSENS EasyQ MRSA is CE marked and bioMérieux will be submitting for 510(k) approval with the U.S. Food and Drug Administration in the first half of 2010. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2966713 Thu, 05 Nov 2009 23:00:00 +0100 2966713 http://www.medworm.com/index.php?rid=2954046&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_203 A world leader in the field of in vitro diagnostics, bioMérieux has appointed Alain Pluquet to the newly created position of Chief Technology Officer (CTO). (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2954046 Mon, 02 Nov 2009 23:00:00 +0100 2954046 http://www.medworm.com/index.php?rid=2934259&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_202 Chromogenic media provides cost-effective MRSA identification for hospitals and labs. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2934259 Tue, 27 Oct 2009 23:00:00 +0100 2934259 http://www.medworm.com/index.php?rid=2908190&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_201 2009 Nine-Month Sales up 7.8% at constant exchange rates and scope of consolidation up 11.2% at constant exchange rates, including business development agreements (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2908190 Mon, 19 Oct 2009 22:00:00 +0100 2908190 http://www.medworm.com/index.php?rid=2823602&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_200 Newly evolved enzymes make some bacteria resistant to all common antibiotics Healthcare workers slow to receive flu vaccines Countries not doing enough to combat “superbugs” About 7 million Healthcare-Associated Infections (HAIs) in the U.S. and Europe each year According to a meeting of over 60 infectious disease experts, the global medical community must act on three imminent threats to patients across the world. First threat: common bacteria, such as Escherichia coli (E. coli) are now producing enzymes which make the bacteria capable of de-activating all but the antibiotics that specialists reserve as a last line of defense. Second threat: healthcare workers themselves may be contributing to the spread of infections by failing to get flu vaccinations and, in some countries, coming... bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2823602 Tue, 22 Sep 2009 22:00:00 +0100 2823602 http://www.medworm.com/index.php?rid=2772092&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_199 Growth in sales: 10.3 % - At constant exchange rates, including business development agreements 6.0 % - At constant exchange rates and scope of consolidation Growth in operating results before non-recurring items: 16 % (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2772092 Sun, 06 Sep 2009 22:00:00 +0100 2772092 http://www.medworm.com/index.php?rid=2633819&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_198 First-Half 2009 Sales Up 6% at constant exchange rates and scope of consolidation Up 10.3% at constant exchange rates, including business development agreements (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2633819 Thu, 23 Jul 2009 22:00:00 +0100 2633819 http://www.medworm.com/index.php?rid=2587769&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_197 Certification validates high performance test for enhanced food safety. bioMérieux, a world leader in the field of in vitro diagnostics, today announced that an AOAC-RI certification has been granted (No. 060903) to the VIDAS® UP E. coli O157 (Including H7) method for screening beef, selected produce and irrigation water. Food manufacturers in the U.S. and many other countries rely on AOAC-RI certified testing methods to release their products on the market. The new solution is based on recombinant phage protein, the latest technology available for food pathogen screening, which offers unique specificity and sensitivity. E. coli O157:H7 is a potentially lethal strain of Escherichia coli that has caused many food outbreaks in the United States, Canada, Japan, and Europe. (Source: bioMerie... bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2587769 Wed, 08 Jul 2009 22:00:00 +0100 2587769 http://www.medworm.com/index.php?rid=2555571&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_196 bioMérieux, a world leader in the field of in vitro diagnostics, today launched VIDAS® EBV for the detection of the Epstein-Barr virus (EBV). This virus causes 80% of cases of infectious mononucleosis, which is often known as “the kissing disease” because it is transmitted through saliva. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2555571 Mon, 29 Jun 2009 22:00:00 +0100 2555571 http://www.medworm.com/index.php?rid=2504561&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_195 Le Document de référence 2008 de la Société peut être consulté sur le site Internet de l’Autorités des Marchés Financiers (www.amf-france.org) et sur le site Internet de la Société (www.biomerieux.com). (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2504561 Wed, 10 Jun 2009 22:00:00 +0100 2504561 http://www.medworm.com/index.php?rid=2504562&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_194 (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2504562 Tue, 09 Jun 2009 22:00:00 +0100 2504562 http://www.medworm.com/index.php?rid=2468105&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_192 New Molecular Strain Typing Test to Ensure Consistent Quality of Beer.bioMérieux, a world leader in the field of in vitro diagnostics, has launched the DiversiLab® Saccharomyces DNA Fingerprinting kit, which will accurately and reproducibly identify the strain type of yeast used in the brewing of beer. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2468105 Sun, 07 Jun 2009 22:00:00 +0100 2468105 http://www.medworm.com/index.php?rid=2468106&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_193 - THEROS CancerTYPE ID® predicts cancer origin with 75 percent accuracy in patients whose primary cancer was “unknown” using traditional diagnostics. - bioTheranostics, a bioMérieux company that discovers, develops and commercializes new molecular diagnostic tests in oncology, announced that a recent study demonstrated the company’s THEROS CancerTYPE ID® molecular diagnostic test predicted cancer origin with 75 percent accuracy in patients whose primary cancer was initially “unknown” using traditional diagnostics. Findings were presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fl. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2468106 Sun, 31 May 2009 22:00:00 +0100 2468106 http://www.medworm.com/index.php?rid=2456170&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_191 bioMérieux, a world leader in the field of in vitro diagnostics, presented the latest addition to its HIV testing offer at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). NucliSENS EasyQ® HIV-1 v2.0 is a test able to detect even very low viral load levels in AIDS patients, offering one of the highest degrees of sensitivity available today. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2456170 Mon, 18 May 2009 22:00:00 +0100 2456170 http://www.medworm.com/index.php?rid=2456171&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_190 bioMérieux, a world leader in the field of in vitro diagnostics, is building upon its Full Microbiology Lab Automation™ (FMLA) concept by offering a new tool to its customers, LeanSigma® - today’s most recognized process and flow improvement methodology. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2456171 Thu, 14 May 2009 22:00:00 +0100 2456171 http://www.medworm.com/index.php?rid=2456172&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_189 bioMérieux, a world leader in in vitro diagnostics, and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announce the recipient of their 2009 Research Grant, which recognizes excellence and major contributions to progress in the field of clinical microbiology by a young scientist from Eastern Europe. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2456172 Mon, 11 May 2009 22:00:00 +0100 2456172 http://www.medworm.com/index.php?rid=2380162&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_188 La Société annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers son rapport financier annuel au 31 décembre 2008. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2380162 Wed, 29 Apr 2009 22:00:00 +0100 2380162 http://www.medworm.com/index.php?rid=2363849&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_187 Up 6.4% - At constant exchange rates and scope of consolidation. Up 10.6% - At constant exchange rates, including business development agreements. bioMérieux, a global leader in the field of in vitro diagnostics, released its quarterly business review through March 31, 2009. As of March 31, 2009, net sales amounted to €286 million, up 6.4% at constant exchange rates and scope of consolidation (on a like-for-like basis) versus the first quarter of 2008. Factoring in sales related to business development agreements, the increase was 10.6% at constant exchange rates. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2363849 Wed, 22 Apr 2009 22:00:00 +0100 2363849 http://www.medworm.com/index.php?rid=2326863&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_185 New range will simplify testing for the pharmaceutical industry. bioMérieux, a world leader in the field of in vitro diagnostics and a leading provider of microbiological solutions for the pharmaceutical industry, launches two innovative culture media for Media Fill Tests (MFT): TSB 3PTM with Animal Peptones and TSB 3PTM with Vegetable Peptones and a color indicator to enhance efficiency and reduce potential errors. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2326863 Mon, 06 Apr 2009 22:00:00 +0100 2326863 http://www.medworm.com/index.php?rid=2273591&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_184 The Board of Directors of bioMérieux, a global leader in the field of in vitro diagnostics, met on Friday, March 13 to approve the consolidated financial statements for the year ended December 31, 2008. The meeting was chaired by Alain Mérieux and attended by the Statutory Auditors. Strong sales growth: +9.8%, at constant exchange rates, including business development Improved operating margin before non recurring-items at 16.8% of sales Substantial R&D and manufacturing investments Three strategic acquisitions and expansion of international network (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2273591 Sun, 15 Mar 2009 23:00:00 +0100 2273591 http://www.medworm.com/index.php?rid=2117485&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_183 bioMérieux, a global leader in the field of in vitro diagnostics, released its business review for fourth-quarter and full-year 2008. 2008 Sales Up 7.5% at constant exchange rates and scope of consolidation (like-for-like) Up 9.8% at constant exchange rates, including business development agreements (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2117485 Mon, 19 Jan 2009 23:00:00 +0100 2117485 http://www.medworm.com/index.php?rid=2105607&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_182 bioMérieux, a world leader in the field of in vitro diagnostics, is enhancing its TEMPO® line for food quality with the launch of one of the most rapid automated solutions for direct enumeration of yeast and mold. TEMPO YM delivers final results in half the time versus most other methods, including the ISO reference method (ISO 21527). (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2105607 Wed, 14 Jan 2009 23:00:00 +0100 2105607 http://www.medworm.com/index.php?rid=2056769&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_180 At the meeting of the bioMérieux Board of Directors held on December 19, 2008, Alexandre Mérieux was appointed as “Directeur Général Délégué” of the Company. Stéphane Bancel continues to be responsible for all functions in his role as Chief Executive Officer and to chair the bioMérieux Management Committee. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2056769 Sun, 21 Dec 2008 23:00:00 +0100 2056769 http://www.medworm.com/index.php?rid=2056770&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_181 Independent studies validate the utility of Theros BCISM for improving risk stratification of early stage breast cancer patients. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2056770 Sat, 13 Dec 2008 23:00:00 +0100 2056770 http://www.medworm.com/index.php?rid=2022899&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_179 bioMérieux, a world leader in the field of in vitro diagnostics has acquired PML Microbiologicals Inc., a leading provider of culture media and microbiological products in North America for both clinical and industrial applications. This privately held American in vitro diagnostics company has manufacturing and marketing teams based in Portland, Oregon and Toronto, Canada. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2022899 Sun, 07 Dec 2008 23:00:00 +0100 2022899 http://www.medworm.com/index.php?rid=2008455&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_178 bioMérieux, a global leader in the field of in vitro diagnostics, today released its business review for the nine months ended September 30, 2008. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=2008455 Mon, 27 Oct 2008 23:00:00 +0100 2008455 http://www.medworm.com/index.php?rid=1912617&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_178 bioMérieux, a global leader in the field of in vitro diagnostics, today released its business review for the nine months ended September 30, 2008. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1912617 Mon, 27 Oct 2008 23:00:00 +0100 1912617 http://www.medworm.com/index.php?rid=1903628&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_177 bioMérieux, a world leader in the field of in vitro diagnostics, announces the opening of a subsidiary in the United Arab Emirates. A hub for its operations in the Middle East, bioMérieux’s 39th subsidiary will be based in Dubai. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1903628 Wed, 22 Oct 2008 22:00:00 +0100 1903628 http://www.medworm.com/index.php?rid=1873911&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_176 bioMérieux, a world leader in the field of in vitro diagnostics, is proud to announce that it is the recipient of the Frost & Sullivan 2008 North American Market Leadership Award for Pharmaceutical Microbiology. bioMérieux received an overall score of 10.13 out of a possible 12.00 points, the highest overall Frost & Sullivan Competitive Metrics Score in the U.S. Rapid Pharmaceutical Manufacturing Microbiology Tests Market. The Market Leadership Award is given to a company that displays overall excellence in the market leadership process, including the identification of market challenges, drivers and restraints, brand recognition as well as strategy development and methods of addressing market trends. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1873911 Mon, 13 Oct 2008 22:00:00 +0100 1873911 http://www.medworm.com/index.php?rid=1827333&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_175 Prostate cancer is the most prevalent cancer in the United States and the 4th most common worldwide. The combination of a test for a new prostate cancer biomarker, Annexin 3, with the standard screening methods could potentially reduce the number of biopsies conducted by up to 75%, when compared with current screening methods alone. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1827333 Wed, 24 Sep 2008 22:00:00 +0100 1827333 http://www.medworm.com/index.php?rid=1784051&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_174 bioMérieux, a world leader in the field of in vitro diagnostics has acquired the privately held AviaraDx, Inc., a molecular in vitro diagnostics company, based in San Diego, California (USA). AviaraDx’s diagnostic tests, based on their proprietary technologies, are used in the molecular classification of cancers and to assist oncologists in making critical therapeutic decisions. The company has built a molecular R&D lab and a small sales & marketing team, as well as a high complexity Clinical Laboratory Improvement Amendments (CLIA) certified service lab. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1784051 Wed, 10 Sep 2008 22:00:00 +0100 1784051 http://www.medworm.com/index.php?rid=1784052&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_173 bioMérieux (Euronext: BIM), a global leader in the field of in vitro diagnostics, today released its interim financial report for the first six months of 2008. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1784052 Sun, 07 Sep 2008 22:00:00 +0100 1784052 http://www.medworm.com/index.php?rid=1784053&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_172 A world leader in the field of in vitro diagnostics, bioMérieux has appointed Steve Harbin as Corporate Vice President, Quality Management Systems, Health, Safety and Environment and Internal Control, effective July 15, 2008. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1784053 Sun, 31 Aug 2008 22:00:00 +0100 1784053 http://www.medworm.com/index.php?rid=1784054&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_171 bioMérieux, a global leader in the field of in vitro diagnostics, today released its interim review for the six months ended June 30, 2008. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1784054 Tue, 22 Jul 2008 22:00:00 +0100 1784054 http://www.medworm.com/index.php?rid=1784055&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_170 bioMérieux, a world leader in the field of in vitro diagnostics has concluded an agreement to acquire the privately held AB BIODISK, a Swedish in vitro diagnostics company with facilities for research and development, manufacturing and marketing located in Stockholm. This is bioMérieux’s fourth acquisition in under two years. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1784055 Tue, 17 Jun 2008 22:00:00 +0100 1784055 http://www.medworm.com/index.php?rid=1784056&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_169 Professor Christian Bréchot has been appointed to the Board of Directors of bioMérieux S.A. during its Annual Shareholder’s Meeting, held on June 12th. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1784056 Thu, 12 Jun 2008 22:00:00 +0100 1784056 http://www.medworm.com/index.php?rid=1784057&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_168 bioMérieux, a world leader in the field of in vitro diagnostics, is enhancing its line of food safety solutions with the launch of two innovative chromogenic culture media, chromID™ Sakazakii and chromID™ Vibrio. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1784057 Wed, 11 Jun 2008 22:00:00 +0100 1784057 http://www.medworm.com/index.php?rid=1784058&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_167 bioMérieux, a world leader in the field of in vitro diagnostics, will unveil a new suite of “Full Microbiology Laboratory Automation” solutions at the 108th General Meeting of the American Society for Microbiology (ASM), held June 1-5 in Boston. bioMérieux believes that full microbiology laboratory automation is imperative to streamlining operations and making more reliable results available faster, particularly in light of the growing threat of healthcare-associated infections. Enhanced automation offsets an increasing lack of specialized personnel, contributing to the control of healthcare expenditures. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1784058 Wed, 28 May 2008 22:00:00 +0100 1784058 http://www.medworm.com/index.php?rid=1784059&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_166 bioMérieux, a leader in the field of in vitro diagnostics and FIND (the Foundation for Innovative New Diagnostics), a Swiss non-profit foundation, have signed a Memorandum of Understanding to jointly undertake development projects in the field of infectious disease diagnostics. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1784059 Wed, 14 May 2008 22:00:00 +0100 1784059 http://www.medworm.com/index.php?rid=1784060&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_165 Sales up 6.2% like-for-like. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1784060 Mon, 28 Apr 2008 22:00:00 +0100 1784060 http://www.medworm.com/index.php?rid=1784061&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_163 (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1784061 Mon, 14 Apr 2008 22:00:00 +0100 1784061 http://www.medworm.com/index.php?rid=1784062&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_164 A team of researchers from the University of Sunderland and bioMérieux, a leading company in the field of in vitro diagnostics, have achieved a new step in the fight against Pseudomonas aeruginosa, a bacterium responsible for deadly healthcare-associated infections, which kills tens of thousands of people throughout the world every year .1 (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1784062 Wed, 02 Apr 2008 22:00:00 +0100 1784062 http://www.medworm.com/index.php?rid=1784064&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_162 bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics has entered into a long-term strategic partnership with Hitachi High-Technologies Corporation of Japan. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1784064 Sun, 16 Mar 2008 23:00:00 +0100 1784064 http://www.medworm.com/index.php?rid=1784063&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_161 2007: Clear improvement in growthand in operating margin before non-recurring items (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1784063 Sun, 16 Mar 2008 23:00:00 +0100 1784063 http://www.medworm.com/index.php?rid=1784065&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_160 bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, has received 510(k) clearance from the U.S. Food and Drug Administration to market VIDAS® NT-proBNP, a test that helps the diagnosis of heart failure. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1784065 Wed, 12 Mar 2008 23:00:00 +0100 1784065 http://www.medworm.com/index.php?rid=1784066&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_159 bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, announces the opening of a subsidiary in Singapore. This 38th subsidiary is another milestone for the company’s international expansion. It will also advance bioMérieux’s Asian development strategy, following recent announcements of joint ventures in China and Japan. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1784066 Wed, 05 Mar 2008 23:00:00 +0100 1784066 http://www.medworm.com/index.php?rid=1784067&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_158 bioMérieux, a world leader in industrial microbiology control, announces that the first Food Safety Handbook: Microbiological Challenges is now available for food professionals. Published by bioMérieux Editions, the handbook was developed with contributions from 24 internationally renowned experts. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1784067 Mon, 25 Feb 2008 23:00:00 +0100 1784067 http://www.medworm.com/index.php?rid=1784068&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_157 bioMérieux (Euronext: BIM) and Wescor, an ELITech Group Company have signed an agreement by which bioMérieux will become Wescor’s exclusive worldwide partner for marketing two customized slide stainer instruments for Gram and tuberculosis bacillus under the bioMérieux brand. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1784068 Wed, 13 Feb 2008 23:00:00 +0100 1784068 http://www.medworm.com/index.php?rid=1784069&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_156 Shanghai Kehua Bio-engineering (Stock Code: 002022) and bioMérieux (Euronext: BIM) announce the creation of a Shanghai-based joint venture to which bioMérieux will transfer microplate immunoassay manufacturing currently located at its Boxtel site in the Netherlands. (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1784069 Wed, 30 Jan 2008 23:00:00 +0100 1784069 http://www.medworm.com/index.php?rid=1784070&cid=s_37963_70_f&fid=37963&url=http%3A%2F%2Fwww.biomerieux.com%2Fservlet%2Fsrt%2Fbio%2Fportail%2FdynPage%3Fopen%3DPRT_NWS_REL%26doc%3DPRT_NWS_REL_G_PRS_RLS_155 (Source: bioMerieux Press Releases) bioMerieux Press Releases news http://www.medworm.com/rss/comments.php?id=1784070 Mon, 21 Jan 2008 23:00:00 +0100 1784070